Fmr LLC Boosts Stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Fmr LLC grew its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 370.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 27,261 shares of the biopharmaceutical company’s stock after purchasing an additional 21,462 shares during the period. Fmr LLC’s holdings in Inovio Pharmaceuticals were worth $158,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of INO. SG Americas Securities LLC purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $71,000. The Manufacturers Life Insurance Company acquired a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at $82,000. Signature Estate & Investment Advisors LLC purchased a new stake in Inovio Pharmaceuticals during the 2nd quarter worth approximately $88,000. Cornercap Investment Counsel Inc. acquired a new position in Inovio Pharmaceuticals during the second quarter worth about $184,000. Finally, American Century Companies Inc. grew its holdings in Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares in the last quarter. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.84 on Monday. The company has a 50-day simple moving average of $4.53 and a 200-day simple moving average of $6.82. Inovio Pharmaceuticals, Inc. has a 12 month low of $1.74 and a 12 month high of $14.75. The company has a market cap of $48.02 million, a PE ratio of -0.53 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of research firms have commented on INO. HC Wainwright decreased their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th. Oppenheimer cut their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. Finally, Royal Bank of Canada reduced their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Inovio Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $38.00.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.